Functional drug–gene interactions in lung cancer

References

• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Marshall E. Cancer research and the $90 billion metaphor. Science331(6024), 1540–1541 (2011).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med.359(13), 1367–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell19(6), 754–764 (2011).
   PubMed Web of Science ®Google Scholar
• Richardson GE, Johnson BE. The biology of lung cancer. Semin. Oncol.20(2), 105–127 (1993).
   PubMedGoogle Scholar
• Bergh JC. Gene amplification in human lung cancer. The Myc family genes and other proto-oncogenes and growth factor genes. Am. Rev. Respir. Dis.142(6 Pt 2), S20–S26 (1990).
   PubMed Web of Science ®Google Scholar
• Kim YH, Girard L, Giacomini CP et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of Myc family gene amplification. Oncogene25(1), 130–138 (2006).
   PubMed Web of Science ®Google Scholar
• Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin. Oncol.28(2 Suppl. 4), S3–S13 (2001).
   PubMed Web of Science ®Google Scholar
• Pei J, Balsara BR, Li W et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer31(3), 282–287 (2001).
   PubMed Web of Science ®Google Scholar
• Garnis C, Lockwood WW, Vucic E et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int. J. Cancer118(6), 1556–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Lacroix L, Commo F, Soria JC. Gene expression profiling of non-small-cell lung cancer. Expert Rev. Mol. Diagn.8(2), 167–178 (2008).
   Web of Science ®Google Scholar
• De Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature467(7315), 543–549 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu J, Ding J, Ding F. Tumor stem cell, or its niche, which plays a primary role in tumorigenesis? World J. Gastrointest. Oncol.2(5), 218–221 (2010).
   Google Scholar
• Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J. Natl Cancer Inst.102(7), 464–474 (2010).
   PubMed Web of Science ®Google Scholar
• Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med.356(1), 11–20 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu CQ, Ding K, Strumpf D et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol.28(29), 4417–4424 (2010).
   PubMed Web of Science ®Google Scholar
• Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of Phase 3 trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol.19(6), 1734–1742 (2001).
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res.67(20), 9609–9612 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol. Biol.448, 63–76 (2008).
   PubMedGoogle Scholar
• Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer71(1), 3–10 (2011).
   PubMed Web of Science ®Google Scholar
• Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell145(1), 19–24 (2011).
   PubMed Web of Science ®Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101(15), 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Mcclellan M, Benner J, Schilsky R et al. An accelerated pathway for targeted cancer therapies. Nat. Rev. Drug Discov.10(2), 79–80 (2011).
   Google Scholar
• Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol.24(8), 985–995 (2006).
   PubMed Web of Science ®Google Scholar
• Bernards R. It’s diagnostics, stupid. Cell141(1), 13–17 (2010).
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction – a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol.3(8), 448–457 (2006).
   PubMedGoogle Scholar
• Mcdermott U, Sharma SV, Dowell L et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA104(50), 19936–19941 (2007).
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res.68(9), 3077–3080 (2008).
   PubMed Web of Science ®Google Scholar
• Luo J, Elledge SJ. Cancer: deconstructing oncogenesis. Nature453(7198), 995–996 (2008).
   Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell136(5), 823–837 (2009).
   PubMed Web of Science ®Google Scholar
• Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell18(6), 548–551 (2010).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med.364(10), 947–955 (2011).
   PubMed Web of Science ®Google Scholar
• Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res.12(14 Pt 2), S4421–S4425 (2006).
   Google Scholar
• Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ343, d7684 (2011).
   PubMedGoogle Scholar
• Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol.12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? Lancet Oncol.12(8), 710–711 (2011).
   PubMedGoogle Scholar
• Lievre A, Bachet JB, Le Corre D et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res.67(6), 2643–2648 (2007).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med.2(1), e17 (2005).
   PubMed Web of Science ®Google Scholar
• Marks JL, Broderick S, Zhou Q et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J. Thorac. Oncol.3(2), 111–116 (2008).
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res.13(10), 2890–2896 (2007).
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol.9(10), 962–972 (2008).
   PubMed Web of Science ®Google Scholar
• Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol.29(31), 4113–4120 (2011).
   PubMed Web of Science ®Google Scholar
• O’byrne KJ, Gatzemeier U, Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol.12(8), 795–805 (2011).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase 3 INTEREST trial. J. Clin. Oncol.28(5), 744–752 (2010).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA. Finding ALK-positive lung cancer: what are we really looking for? J. Thorac. Oncol.6(3), 411–413 (2011).
   PubMedGoogle Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res.14(10), 2895–2899 (2008).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.2(3), e73 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.352(8), 786–792 (2005).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA104(52), 20932–20937 (2007).
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res.68(22), 9479–9487 (2008).
   PubMed Web of Science ®Google Scholar
• Noro R, Gemma A, Miyanaga A et al.PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int. J. Oncol.31(5), 1157–1163 (2007).
   PubMedGoogle Scholar
• Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol.1(7), 629–634 (2006).
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355(10), 983–991 (2006).
   PubMed Web of Science ®Google Scholar
• Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a Phase 3 trial in non-small-cell lung cancer. J. Clin. Oncol.25(19), 2747–2754 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature455(7216), 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol.22(12), 2616–2624 (2011).
   PubMed Web of Science ®Google Scholar
• Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature450(7171), 893–898 (2007).
   PubMed Web of Science ®Google Scholar
• Kan Z, Jaiswal BS, Stinson J et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature466(7308), 869–873 (2010).
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer3(1), 11–22 (2003).
   PubMed Web of Science ®Google Scholar
• Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc.6(2), 201–205 (2009).
   PubMedGoogle Scholar
• Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett.585(1), 1–6 (2011).
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer5(9), 689–698 (2005).
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol.8, 38 (2010).
   PubMedGoogle Scholar
• Canaani D. Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br. J. Cancer100(8), 1213–1218 (2009).
   Google Scholar
• Farmer H, Mccabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature434(7035), 913–917 (2005).
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
   PubMed Web of Science ®Google Scholar
• Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology (Williston Park)25(11), 1014–1025 (2011).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat. Med.14(12), 1351–1356 (2008).
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res.68(18), 7409–7418 (2008).
   PubMed Web of Science ®Google Scholar
• Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell147(1), 26–31 (2011).
   PubMed Web of Science ®Google Scholar
• Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev.21(1), 34–41 (2011).
   Web of Science ®Google Scholar
• Mizuarai S, Kotani H. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum. Genet.128(6), 567–575 (2010).
   Google Scholar
• Westbrook TF, Stegmeier F, Elledge SJ. Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb. Symp. Quant. Biol.70, 435–444 (2005).
   PubMedGoogle Scholar
• Muellner MK, Uras IZ, Gapp BV et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol.7(11), 787–793 (2011).
   PubMed Web of Science ®Google Scholar
• Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl Acad. Sci. USA108(37), E699–E708 (2011).
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Santiago S et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med.17(9), 1116–1120 (2011).
   Google Scholar
• Lundberg AS, Randell SH, Stewart SA et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene21(29), 4577–4586 (2002).
   PubMedGoogle Scholar
• Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature448(7153), 561–566 (2007).
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.28(10), 1069–1078 (2010).
   PubMed Web of Science ®Google Scholar
• Lehner B, Crombie C, Tischler J, Fortunato A, Fraser AG. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat. Genet.38(8), 896–903 (2006).
   PubMed Web of Science ®Google Scholar
• Costanzo M, Baryshnikova A, Bellay J et al. The genetic landscape of a cell. Science327(5964), 425–431 (2010).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet366(9496), 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J.8(2), 129–138 (2008).
   PubMed Web of Science ®Google Scholar
• Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res.64(24), 9139–9143 (2004).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol.26(7), 1119–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Cusatis G, Brahmer J et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther.6(3), 432–438 (2007).
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res.12(7 Pt 1), 2166–2171 (2006).
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ.15(3), 504–514 (2008).
   PubMed Web of Science ®Google Scholar
• Carette JE, Guimaraes CP, Varadarajan M et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science326(5957), 1231–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Carette JE, Guimaraes CP, Wuethrich I et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat. Biotechnol.29(6), 542–546 (2011).
   Google Scholar
• Derose YS, Wang G, Lin YC et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med.17(11), 1514–1520 (2011).
   PubMed Web of Science ®Google Scholar
• Puyol M, Martin A, Dubus P et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell18(1), 63–73 (2010).
   PubMed Web of Science ®Google Scholar
• Meylan E, Dooley AL, Feldser DM et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature462(7269), 104–107 (2009).
   PubMed Web of Science ®Google Scholar
• Basseres DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-κB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res.70(9), 3537–3546 (2010).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res.67(24), 11924–11932 (2007).
   PubMed Web of Science ®Google Scholar
• Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res.65(14), 6401–6408 (2005).
   PubMed Web of Science ®Google Scholar
• Paul I, Savage KI, Blayney JK et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J. Pathol.224(4), 564–574 (2011).
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Faber AC, Li D et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res.70(6), 2485–2494 (2010).
   PubMed Web of Science ®Google Scholar
• De Raedt T, Walton Z, Yecies JL et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell20(3), 400–413 (2011).
   PubMed Web of Science ®Google Scholar
• Park KS, Martelotto LG, Peifer M et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med.17(11), 1504–1508 (2011).
   PubMed Web of Science ®Google Scholar
• Huang S, Ren X, Wang L, Zhang L, Wu X. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Cancer Prev. Res. (Phila.)4(5), 666–673 (2011).
   Google Scholar